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Abstract
KG-1a, HL-60 and U-937 cells, which represent different stages of myelopoiesis, showed growth retardation in response to
the coumarin antibiotic novobiocin. Novobiocin was found to increase CD38 expression (in all three cell lines) and to induce
differentiation along the monocytic path in HL-60 and U-937 cells but not in KG-1a cells. The increase in surface expression
of CD38 was matched by NAD glycohydrolase activity and by increases in the level of specific mRNA, indicating that the
gene product is active and that regulation occurs at the level of transcription or mRNA stability. Of the three cell lines tested,
only the early KG-1a expressed N-cadherin, a member of Ca2-dependent adhesion molecules involved in embryonic
differentiation processes. In contrast to CD38, N-cadherin was slightly down-regulated pointing to a specific role of
novobiocin in gene regulation. ß 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
It is known that human myelogenous leukemia
cells are unable to di¡erentiate to functional mature
cells. The arrest in maturation, which can occur at
any stage of di¡erentiation, is accompanied by un-
controlled cell proliferation. We studied the induc-
tion of di¡erentiation and inhibition of proliferation
by novobiocin using cells from three myeloid leuke-
mia lines blocked at di¡erent stages of maturation.
The coumarin novobiocin has many pharmacological
e¡ects [1^3], other than its known ability to interfere
with topoisomerase II, a major nuclear sca¡old pro-
tein related to cell cycle progression [4]. It has been
shown to inhibit the poly(ADP-ribose) synthetase
(EC 2.4.2.30) and more speci¢cally the mono(ADP-
ribosyl) transferase (EC 2.4.2.31) [5]. The enzymes
catalyze the covalent attachment of multiple or single
residues, respectively, of the ADP-ribose moiety of
NAD to various proteins. This in turn modulates
the functions of the target proteins. According to
Grosso and Pitot [6] and Shima et al. [7], several
inhibitors of ADP-ribosylation are capable of induc-
ing di¡erentiation of the promyelocytic leukemia
HL-60 cells into granulocytic cells. We asked
whether novobiocin shares this ability and whether
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KG-1a cells, arrested at an undi¡erentiated myeloid
blast stage, and the U-937 cell line, an established
human monoblast cell line derived from the pleural
exudate of a patient with di¡use histiocytic lympho-
ma, are similarly a¡ected by novobiocin. Besides
measuring its e¡ect on proliferation and di¡erentia-
tion we considered the possibility that novobiocin
might induce expression of CD38, a surface antigen
that has been associated with growth and di¡erentia-
tion of lymphoid precursors [8,9].
CD38 is a type II glycoprotein possessing ecto-
NAD glycohydrolase activity [10]. It also catalyzes
the transient formation of cyclic ADP-ribose [11],
suggesting the involvement of the ectoenzyme in
the regulation of Ca2 homeostasis [12]. CD38 has
a rather peculiar pattern of expression and is found
in either earlier or late, but not in intermediate stages
during B and T cell di¡erentiation [8,13^15]. In HL-
60 cells, a rapid increase in CD38 expression occurs
in response to ATRA, a biologically active metabo-
lite of vitamin A that e¡ects granulocytic di¡erentia-
tion [16^18]. Recently, IFN-Q and 1K,25-dihydroxy-
vitamin D3 (1,25(OH2)D3), which are e¡ectors of
HL-60 monocytic di¡erentiation, have also been re-
ported to induce CD38 expression [19,20]. The incon-
sistent expression on lymphocytes suggests that
CD38 plays a role in di¡erentiation and mature im-
mune function.
Apart from CD38 our interest has focused on
N-cadherin, an adhesion molecule found to control
not only physical cell^cell interaction but also to
participate directly in the di¡erentiation of certain
types of tissues. N-Cadherin belongs to the family
of classical Ca2-dependent cadherins and is ex-
pressed transiently during di¡erent developmental
stages in ontogenesis [21]. So far, the expression of
N-cadherin during di¡erentiation of myelomonocytic
cell lines has not been described.
In the present study we identi¢ed novobiocin as an
agent with antiproliferative properties that has the
ability to induce myeloid leukemia cell lines to di¡er-
entiate along the monocytic path dependent of the
stage of myeloid commitment. The early KG-1a cells
in contrast to HL-60 and U-937 cells were com-
pletely resistant to di¡erentiation. However, they re-
sponded to novobiocin by expressing CD38, a mole-
cule tightly regulated during hematopoietic cell
di¡erentiation.
2. Materials and methods
2.1. Cell culture
HL-60 and U-937 cells were cultured in RPMI
1640 medium (Sigma, Deisenhofen, Germany) sup-
plemented with 10% FCS, 2 mM L-glutamine, 100
U/ml penicillin and 100 Wg/ml streptomycin. KG-1a
cells were propagated in Iscove’s modi¢ed Dulbec-
co’s medium (Sigma) supplemented with 20% FCS,
2 mM L-glutamine, 100 U/ml penicillin and 100 Wg/
ml streptomycin. Cells were seeded into £asks at a
density of 2^4U105/ml and then incubated at 37‡C in
a humidi¢ed 5% CO2 atmosphere in the absence or
presence of novobiocin, ATRA, DMSO, rifampicin,
actinomycin, PMA, dexamethasone or hydroxyurea
(Sigma) for the times indicated.
For treatment with Bacillus subtilis phosphatidyl-
inositol speci¢c phospholipase C (PIPLC) (ICN,
Eschwege, Germany), the enzyme (5 U/ml) was
added twice to the cell culture (4U105/ml) during a
3 day incubation.
2.2. Monoclonal antibodies
The murine monoclonal antibody sources were as
follows: isotope control IgG1, anti-N-cadherin
(GC4) (Sigma); anti-CD18, -CD34, -CD38, -CD64,
-CD67, -CD86 (Immunotech, Hamburg, Germany);
anti-CD14 (BL-M/G14), anti-CD11b (BL-M/G1)
(DiaMak, Leipzig, Germany); anti-HLA-DR/DP/
DQ (FITC); MCA477 (Serotec, Oxford, UK).
2.3. Immuno£uorescence labeling
Cells (2U105) were incubated in the presence of
the indicated monoclonal antibody for 45 min at
4‡C. Cells were then washed in PBS containing
10% Haemaccel (Hoechst, Frankfurt, Germany)/
0.1% sodium azide. When using an unlabeled pri-
mary antibody, cells were further incubated for 30
min at 4‡C with FITC-labeled goat anti-mouse sec-
ondary antibody (Si¢n, Berlin, Germany). After
washing and ¢xation in 1% formaldehyde, cells
were analyzed on a FACScan (Becton Dickinson,
San Jose, CA, USA). Cells were gated according to
their scatter light, and £uorescence intensity distribu-
tion was analyzed in histograms.
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2.4. NAD glycohydrolase (NADase) activity
NADase activity was measured by a £uorometric
method as described [22] with minor modi¢cations.
The reaction mixture contained 1U106 cells and 10
WM O-NAD in a volume of 400 Wl assay bu¡er con-
sisting of 50 mM Tris^HCl (pH 7.5) and 0.03% Tri-
ton X-100. The reaction was started by the addition
of O-NAD, and cleavage of O-NAD was followed in
an LS 50B luminescence spectrometer (Perkin-Elmer,
Foster City, CA, USA). The excitation wavelength
was 310 nm and the emission was recorded at 410
nm. One relative unit of NADase activity was de-
¢ned as the initial slope of the £uorescence increase
obtained in the presence of 0.1 unit NADase of Neu-
rospora crassa (Sigma).
2.5. RT-PCR
Total RNA was isolated from 3U106 cells using
the RNeasy mini kit (Qiagen, Hilden, Germany) ac-
cording to the manufacturer’s instructions. cDNA
was prepared by annealing of RNA with oligo(dT)20
(MWG Biotech, Ebersberg, Germany) for 10 min at
70‡C and reverse transcription using Superscript II
reverse transcriptase (Gibco BRL, Karlsruhe, Ger-
many) for 60 min at 37‡C with an inactivation phase
of 4 min at 94‡C. For PCR ampli¢cation an aliquot
of each RT sample was added to the reaction mix-
ture containing 1.5 mM MgCl2, 200 WM dNTP, 1 WM
of each primer and 1 unit Taq DNA polymerase
(Gibco BRL). Primers were: 5P-ACC CCG CCT
GGA GCC CTA TG-3P and 5P-GCT AAA ACA
ACC ACA GCG ACT GG-3P for CD38 [23] and
5P-AAC AGC GAC ACC CAC TCC TC-3P and
5P-GGA GGG GAG ATT CAG TGT GGT-3P for
GAPDH, 5P-GAC TGG GTC ATC CCT CCA
AT-3P and 5P-ATA GAG ATA AAA ACC TTT
CA-3P for N-cadherin [24]. All primer pairs used
were intron spanning. Reactions were performed in
a DNA thermal cycler Crocodile III (Oncor Appli-
gene, Heidelberg, Germany) for GAPDH and N-cad-
herin and in a cycler T-gradient (Biometra, Go«tting-
en, Germany) for CD38 under the following
conditions. All reactions started with a ¢rst denatur-
ation phase of 2 min at 95‡C. Ampli¢cation of
CD38: 25 cycles of 60 s at 95‡C, 60 s at 68‡C and
90 s at 72‡C with a prolongation of 2 s every cycle.
Ampli¢cation of GAPDH: 15 cycles of 60 s at 95‡C,
60 s at 60‡C and 90 s at 72‡C with a prolongation of
10 s every ¢ve cycles. Ampli¢cation of N-cadherin:
20 cycles of 60 s at 95‡C, 60 s at 50‡C and 90 s at
72‡C with a prolongation of 10 s every ¢ve cycles.
The ¢nal extension phase for all reactions was 15
min at 72‡C. The PCR products were separated by
electrophoresis on 1.8% agarose gels (FMC Bioprod-
ucts, Rockland, MA, USA), stained for 10 min in
1 Wg/ml ethidium bromide and visualized under UV
light.
3. Results
The e¡ect of novobiocin on the growth of KG-1a,
HL-60 and U-937 cells was determined by thymidine
incorporation assay following 4 day exposure to no-
vobiocin concentrations up to 0.25 mM (Table 1), a
dose previously shown to inhibit TNF-K production
in endotoxin-stimulated human monocytes [25]. HL-
60 and U-937 cells were similarly a¡ected, with mild
but signi¢cant reductions in DNA synthesis follow-
ing treatment with 0.07 mM, and an approx. 3^4-
fold decrease with 0.13 mM. A further doubling of
the dose resulted in a 20-fold reduction in DNA syn-
Table 1
E¡ect of novobiocin on [3H]thymidine uptake in KG-1a, HL-60, and U-937 cells
Novobiocin (mM) 3H incorporation (cpmU1033)
KG-1a HL-60 U-937
None 230.39 þ 4.99 62.77 þ 2.39 147.12 þ 15.38
0.07 217.01 þ 10.03 45.54 þ 7.56 113.82 þ 10.07
0.13 213.40 þ 8.36 15.24 þ 2.70 54.41 þ 6.34
0.25 59.42 þ 6.21 0.31 þ 0.06 2.67 þ 0.60
Cells (1U106/ml) were incubated for 4 days in the absence or presence of 0.07 mM, 0.13 mM and 0.25 mM novobiocin. Twenty-four
hours before harvesting, cultures were given 1 WCi/well [3H]thymidine as described [39]. Results are means þ S.D. of triplicate samples.
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thesis. The growth of the early blast cells KG-1a was
less susceptible, with only mild e¡ects seen with no-
vobiocin concentrations up to 0.13 mM. However,
the 0.25 mM dose once again resulted in marked
reduction in DNA synthesis to around 25% of con-
trol level. These reductions in thymidine incorpora-
tion were re£ected by decreases in cell numbers,
which were 90%, 60% and 50% of control levels in
the KG-1a, HL-60 and U-937 cultures, respectively,
following 4 day exposure to 0.13 mM novobiocin.
Cell viability as judged by trypan blue exclusion
was una¡ected, suggesting that the reduction in cell
number is due to cytostatic rather than cytotoxic
e¡ects.
To test whether novobiocin was capable of induc-
ing di¡erentiation of the cells along the granulocytic
or monocytic path we measured the expression of a
range of di¡erentiation markers on all three cell lines
(Table 2). Following 4 days of growth in 0.13 mM
novobiocin, cells from each line were stained with
antibodies speci¢c for a range of surface markers
of the macrophage or granulocyte lineages: CD11b
(adhesion molecule, monocyte), CD18 (adhesion
molecule, monocyte, weakly expressed on granulo-
cytes), CD14 (LPS receptor, monocyte), CD64 (FcQ
receptor, monocyte), CD67 (non-speci¢c cross-react-
ing antigens, NCAs, granulocyte), CD86 (co-stimu-
lation of T cells, monocyte), and HLA class II
(monocyte). In general, the extent of surface antigen
induction on each cell line paralleled the degree of
inhibition of DNA synthesis described above. While
the majority of U-937 cells (being committed to the
monocyte/macrophage lineage) already express the
macrophage markers CD11b and CD18, novobiocin
treatment led to large increases in the frequencies of
cells expressing all other macrophage antigens tested,
indicating the induction of further maturation along
the macrophage lineage. The e¡ects of novobiocin on
HL-60 cells were very similar, though less strong,
and the antigenic pro¢les measured suggest that the
HL-60 di¡erentiation under these conditions is pre-
dominantly monocytic. E¡ects on the progenitor-like
cell line KG-1a were limited to moderate increases in
the surface expression of CD11b and CD64.
Another surface antigen that has been described as
a di¡erentiation marker is CD38. Upon treatment
with novobiocin its expression was found to be in-
creased in all three cell lines tested. While for the
majority of the di¡erentiation antigens tested both
the expression and induction levels were highest in
the more di¡erentiated cell types, the expression of
CD38 was an exception, being highest in novobiocin-
treated KG-1a cells.
To determine whether the increased surface expres-
sion of CD38 was re£ected in increased levels of
enzymatic activity, ecto-NAD hydrolase assays were
Fig. 1. CD38 expression and ecto-NADase activity on KG-1a
cells, treated with novobiocin and ATRA. (A) After incubation
of KG-1a cells (2U105/ml) in the absence or presence of 0.25
mM novobiocin or 100 nM ATRA for the indicated times, sur-
face antigen expression was analyzed using a monoclonal anti-
body against CD38. (B) Samples of the same cultures were in-
cubated with O-NAD for assay of NADase activity. The bars
indicate the mean þ S.D. of duplicate samples. The data shown
in A and B are from one representative experiment out of
three.
Table 2
Expression of surface antigens on KG-1a, HL-60, and U-937
cells after treatment with novobiocin
Surface antigen % positive cells
KG-1a HL-60 U-937
CD11b 13 (3) 45 (1) 99 (93)
CD18 99 (99) 76 (6) 99 (72)
CD14 3 (1) 12 (1) 34 (2)
CD38 23 (7) 15 (0) 12 (0)
CD64 14 (3) 10 (1) 60 (4)
CD67 1 (1) 4 (1) 2 (0)
CD86 3 (2) 17 (8) 62 (16)
MHC II 0 (0) 21 (3) 71 (5)
KG-1a, HL-60 and U-937 cells (4U105/ml) were cultured in the
absence or presence of 0.13 mM novobiocin for 4 days. Surface
expression of the antigens was analyzed using monoclonal anti-
bodies against CD11b, CD18, CD14, CD38, CD64, CD67,
CD86, and HLA DR/DP/DQ. Percent positive cells were calcu-
lated in relation to isotype matched control antibodies. Un-
treated controls are shown in parentheses. The data shown are
from one representative experiment out of three.
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performed in parallel to anti-CD38 antibody binding
studies on KG-1a cells induced with either ATRA (a
potent agent known to induce CD38) or novobiocin.
The results con¢rm that the increase in surface CD38
correlates closely to an increase in NAD hydrolase
activity (Fig. 1). Furthermore, they show that the
accumulation of surface CD38 in response to novo-
biocin is both delayed and reduced compared to that
in response to ATRA. This can be seen more clearly
from the induction kinetics presented in Fig. 2A, in
which FACS analyses of surface CD38 expression
following treatment with 0.13 mM and 0.25 mM no-
vobiocin are compared to those following 100 nM
ATRA treatment over a time course of 3 days. The
induction of CD38 by both ATRA and novobiocin
can be seen on the level of mRNA as demonstrated
by RT-PCR (Fig. 2B).
To test whether this change in gene transcription is
secondary to a primary cytostatic e¡ect, KG-1a cells
were incubated in the presence of a panel of chem-
icals known to inhibit cell proliferation (Table 3).
Among the antileukemic chemotherapeutic agents
tested only dexamethasone and hydroxyurea induced
CD38 expression whereas actinomycin and rifampi-
cin had no e¡ect. Neither did phorbol 12-myristate
13-acetate (PMA) nor DMSO, two inducers of mye-
loid leukemia cell di¡erentiation that inhibit cell pro-
liferation, lead to an increased CD38 expression.
Thus, the induction of CD38 expression is not a
mere consequence of a cytostatic e¡ect. Moreover,
as arrest in the G1 phase is a common property of
dexamethasone [26], hydroxyurea [27], DMSO [28]
and PMA [29] shared by novobiocin [30], this inhi-
bition of cell cycle progression at a speci¢c stage is
neither responsible for CD38 induction.
Since novobiocin is capable of inhibiting ADP-ri-
Fig. 2. Novobiocin- and ATRA-induced expression of CD38 in KG-1a cells. (A) Cells (2U105/ml) were incubated with medium, 0.13
mM novobiocin, 0.25 mM novobiocin or 100 nM ATRA for 1, 2 or 3 days. Surface antigen expression was analyzed using a mono-
clonal antibody against CD38 (solid area) and the corresponding isotype control (open area). Isotype controls of di¡erently treated
cells were comparable. (B) KG-1a cells (2U105/ml) were incubated with either medium, 0.25 mM novobiocin or 100 nM ATRA. After
1 or 3 days RNA was isolated followed by reverse transcription of mRNA. PCR was performed with speci¢c primers for CD38 and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The data shown are from one representative experiment out of three.
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bosyltransferases we assumed that inhibiting these
enzymes could lead to CD38 induction. To address
this possibility, KG-1a cells were treated with phos-
pholipase C to remove GPI-anchored proteins and
thereby most ADP-ribosyltransferases from the cell
surface. However, this treatment was not su⁄cient to
induce CD38 expression (Fig. 3). These data suggest
that inhibition of external ADP-ribosyltransferases
has no in£uence on CD38 expression, but they do
not exclude a role of such enzymes located within the
cell.
Besides the typical di¡erentiation antigens found
on leukocytes, we measured the surface expression
of N-cadherin. This cell adhesion molecule has been
reported to be involved in embryonic di¡erentiation
processes [21] but its expression during hematopoie-
sis has not been described so far. We found that
N-cadherin is only expressed on the early myeloid
blast cell line KG-1a (Fig. 4A), whereas it is absent
from the more di¡erentiated cells HL-60 and U-937
(not shown). Incubation of KG-1a cells with novo-
biocin results in a slight reduction of N-cadherin sur-
face expression supporting the role of novobiocin in
the induction of a more di¡erentiated cell type. In-
terestingly, the speci¢c inducer of CD38, ATRA, also
induced a reduction in N-cadherin expression. The
slight down-regulation of N-cadherin in KG-1a cells
induced by both novobiocin and ATRA was con-
¢rmed by the decrease in N-cadherin mRNA levels
(Fig. 4B).
4. Discussion
The CD38 antigen follows a strict pattern of ex-
pression in lymphoid lineages, being present transi-
ently during early lymphoid di¡erentiation and again
on mature T and B cells [8,13^15]. In addition, line-
age committed myeloid progenitor cells express very
high levels of CD38, which then decrease as matura-
tion progresses [31,32]. CD38 has also been reported
to be present on the malignant counterparts of these
hematopoietic cells [33]. Factors responsible for reg-
ulating such remarkable changes in CD38 expression
Fig. 3. Phospholipase C treatment has no in£uence on CD38
expression on KG-1a cells. Cells (4U105/ml) were incubated in
the absence or presence of phosphatidylinositol speci¢c phos-
pholipase C (5 U/ml) for 3 days. Surface antigen expression
was analyzed using a monoclonal antibody against CD38 (solid
area) and the corresponding isotype control (open area). Iso-
type controls of di¡erently treated cells were comparable.
Table 3
E¡ect of various chemicals on cell proliferation and CD38 expression
Chemical (concentration) Number of viable cells (% of control cells) CD38 (% positive cells)
Treated Untreated
Dexamethasone (2 WM) 76 þ 10 6.7 þ 2.4 2.5 þ 0.6
Hydroxyurea (79 WM) 48 þ 13 8.0 þ 1.2 3.0 þ 0.6
Actinomycin (100 WM) 47 þ 20 4.5 þ 2.5 3.1 þ 1.0
Rifampicin (100 nM) 83 þ 6 3.5 þ 0.2 3.4 þ 0.5
PMA (1.5 Wg/ml) 81 þ 3 2.3 þ 0.8 2.9 þ 1.1
DMSO (1%) 31 þ 3 2.4 þ 1.2 2.3 þ 1.0
KG-1a cells (4U105/ml) were cultured in the absence or presence of various chemicals for 3 days. Viable cell counts were performed
using trypan blue dye exclusion. Percent CD38 positive cells were calculated in relation to isotype matched control antibodies. Values
are the mean þ S.D. of four separate experiments.
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and its function are unknown. The steroid ATRA
has been identi¢ed as a potent regulator for CD38
expression in vitro and perhaps in vivo [16^18]. It
leads to a signi¢cant increase in CD38 expression
in leukemic cells of patients with acute promyelocytic
leukemia [17] and induces remission in a majority of
these patients [34,35]. In how far these two events are
causally related is not clear.
The increase in CD38 expression also implies the
acquirement of new functional properties like pro-
duction of biologically active NAD degradation
products, i.e. cADPR, nicotinamide and ADP-ribose,
and binding to natural ligands that could in£uence
normal and leukemic myelopoiesis [36].
Here we show that an unrelated compound, novo-
biocin, also induces CD38 expression in KG-1a,
U-937 and HL-60 cells, albeit to a smaller extent.
In KG-1a cells both ATRA and novobiocin reduce
the expression of a second gene coding for the adhe-
sion molecule N-cadherin, suggesting that novobio-
cin in£uences similar processes as are a¡ected by
ATRA. Whereas the latter is considered to be a spe-
ci¢c inducer of CD38 involving the direct binding of
the retinoid acid receptor transcription factor to the
CD38 gene [37], novobiocin a¡ected the expression
of a range of di¡erentiation markers. We found an
increased expression of the monocytoid markers
CD14, CD64, CD86 and MHC II molecules on
both HL-60 and U-937 cells, indicating that novo-
biocin e¡ects monocytoid di¡erentiation. In contrast,
the early myeloid KG-1a blast cells were unable to
up-regulate expression of CD14, CD86 and MHC II
molecules. Similar to KG-1a cells, human CD34
marrow progenitor cells display CD38 overexpres-
sion when exposed to ATRA without undergoing
di¡erentiation [38], suggesting an absence of matura-
tion pressure.
There are a number of ways in which the known
properties of novobiocin may account for its in£u-
ence on gene expression. Within the context of a
Fig. 4. Novobiocin- and ATRA-induced decrease of N-cadherin expression. (A) KG-1a cells (2U105/ml) were incubated with either
medium, 0.13 mM novobiocin, 0.25 mM novobiocin or 100 nM ATRA for 1, 3 or 6 days. Surface antigen expression was analyzed
using a monoclonal antibody against N-cadherin (solid area) and the corresponding isotype control (open area). Isotype controls of
di¡erently treated cells were comparable. (B) KG-1a cells (2U105/ml) were incubated with either medium, 0.25 mM novobiocin or 100
nM ATRA. After 3 days mRNA was isolated and reverse transcribed. PCR was performed with speci¢c primers for N-cadherin and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The data shown are from one representative experiment out of three.
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di¡erentiation program it is quite possible that an
initially general e¡ect may cause a shift in the ex-
pression program that favors the transcription of
some genes and represses others. In line with this,
we could show an increase in a range of cell surface
markers and a decrease in N-cadherin expression at
the protein and mRNA level induced by novobiocin,
and Rius et al. [30] observed that novobiocin in-
creases the level of vimentin mRNA and reduces
the levels of c-myc and L-actin mRNA. The fact
that the increase in surface antigen expression
roughly parallels the degree of inhibition of DNA
synthesis with the more mature cell lines showing a
higher susceptibility than the earlier KG-1a cells to
the e¡ects of novobiocin would be consistent with a
general mechanism of this sort. However, it is un-
likely that the CD38 induction reported here is a
simple consequence of an overall shift towards a
more di¡erentiated phenotype, since not all inducers
of the granulocytic (DMSO, GM-CSF) or monocytic
(IFN-Q, PMA) di¡erentiation of HL-60 cells up-reg-
ulate CD38 [16,17].
Furthermore, we considered the possibility that
CD38 expression was a direct result of inhibition of
cell growth. When testing the in£uence of various
chemicals on cell proliferation and CD38 expression
in KG-1a cells, no correlation between the decrease
in cell number and the induction of CD38 was
found. In line with this, upon treatment of KG-1a
cells with novobiocin, induction of CD38 reached
almost its maximum at a concentration at which no-
vobiocin had no cytostatic e¡ect.
Alternatively, CD38 induction might be related to
another property of novobiocin, the known ADP-
ribosyltransferase inhibitory e¡ect [5], which has
the potential to interfere with particular signaling
pathways and thereby to exert a speci¢c in£uence
on certain subsets of genes. As treatment of KG-1a
cells with phospholipase C, which removes the GPI-
anchored ADP-ribosyltransferases, has no e¡ect on
CD38 expression on KG-1a cells, external ADP-ri-
bosyltransferases do not seem to play a role in this
context. However, it cannot be ruled out that intra-
cellular ADP-ribosylation is involved at some level in
determining regulation of the CD38 gene during
myelomonocytic di¡erentiation. Indeed, our prelimi-
nary experiments show that 3-aminobenzamide, an-
other inhibitor of ADP-ribosylation, which is struc-
turally unrelated to novobiocin, also induces CD38
expression.
Whatever the mechanism, it is clear that the in-
duction of CD38 expression is a speci¢c property
of novobiocin rather than a mere consequence of
its cytostatic e¡ect.
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